Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
168 INR | -1.06% | -1.47% | +4.25% |
Apr. 18 | Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA | MT |
Feb. 14 | Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024 |
Sales 2024 * | 21.58B 259M | Sales 2025 * | 26.33B 316M | Capitalization | 76.95B 924M |
---|---|---|---|---|---|
Net income 2024 * | 3.34B 40.03M | Net income 2025 * | 4.07B 48.8M | EV / Sales 2024 * | 3.57 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.92 x |
P/E ratio 2024 * |
23.1
x | P/E ratio 2025 * |
18.9
x | Employees | 852 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.99% |
Latest transcript on Marksans Pharma Limited
1 day | -1.09% | ||
1 week | -1.47% | ||
Current month | +10.57% | ||
1 month | +16.39% | ||
3 months | +14.25% | ||
6 months | +65.47% | ||
Current year | +4.25% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 52 | 92-04-15 | |
Director of Finance/CFO | 54 | 02-09-05 | |
Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sunny Sharma
BRD | Director/Board Member | 49 | 21-08-10 |
Chief Executive Officer | 52 | 92-04-15 | |
Director/Board Member | 52 | 14-09-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 117 M€ | +0.83% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 168 | -1.06% | 1 588 461 |
24-04-23 | 169.8 | +1.04% | 1,703,066 |
24-04-22 | 168 | -3.59% | 2,963,259 |
24-04-19 | 174.3 | +2.26% | 4,856,047 |
24-04-18 | 170.4 | -3.54% | 9,565,839 |
Delayed Quote NSE India S.E., April 24, 2024 at 05:50 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.25% | 924M | |
+27.92% | 672B | |
+27.04% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.36% | 217B | |
+5.82% | 199B | |
-8.55% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- MARKSANS Stock